Scientific exchange · Dr. Noor Yamamoto

11 Feb 2026 · Phone · Dr. Noor Yamamoto, Institut Curie · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0119—

Capture insight from this engagement

Location: Institut Curie
Therapeutic area: Nephrology
Country: France
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Treatment burden and fatigue
APRIL pathway mechanism
eGFR slope interpretation

Scientific content used

NPH mechanism-of-action deck
Surrogate-endpoint evidence review

Questions raised

No questions recorded.

Notes

Scientific exchange with academic nephrologist at Institut Curie. Discussed treatment burden and fatigue, april pathway mechanism, egfr slope interpretation.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 2
Depth of exchange: 4
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0119

Audit history (0)

All create, update and approval events for this record

No audit events in sample data